Drugs / SmofKabiven Peripheral
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT03792087 | Dec 2017 → Dec 2018 | — | Fresenius Kabi | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT01533298 Comparator | Jul → Dec 2011 | — | JW Life Science | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SmofKabiven Peripheral | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03792087 ↗ |
| Route | Intravenous | “intravenously over 3 days infusion” NCT01533298 ↗ |